Introduction
Acute and delayed nausea and vomiting contribute significantly to the morbidity of patients undergoing autologous and allogeneic hematopoietic stem cell transplantation (HSCT). Typically, a 5-HT3 receptor antagonist and dexamethasone are used as prophylactic antiemetics on each day of the conditioning regimen in which chemotherapy or radiation is administered [1] [2] [3] . The recently published 2017 update to the American Society of Clinical Oncology antiemetic guidelines now recommend that adult patients undergoing HSCT be offered a three-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone, whereas previous recommendations in 2015 did not endorse this approach [4, 5] . The 2016 Multinational Association of Supportive Care in Cancer guidelines recommend the combination of a 5-HT3 receptor antagonist with dexamethasone and aprepitant before chemotherapy for patients receiving high-dose chemotherapy for stem cell transplantation [6] . The dose of aprepitant recommended by these guidelines is 125 mg by mouth for one dose on day 1, then 80 mg by mouth once daily on days 2-4 [6] . In its package insert, oral aprepitant is recommended for 3 consecutive days [7] .
Aprepitant (Emend ® ), a neurokinin-1 (NK 1 ) receptor antagonist, has been shown to prevent acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy when given in standard, outpatient dosing schedules [8] . The safety of an extended duration of aprepitant, a moderate inhibitor of CYP3A4, is unknown when combined with very high doses of cyclophosphamide (CY) and busulfan.
Methods

Design
This was a prospective, randomized, double blind, placebo-controlled parallel pilot study at a single institution, Oregon Health & Science University (OHSU), in Portland, Oregon. Study procedures were approved by the OHSU Institutional Review Board. All patients gave written informed consent prior to participation. The purpose of this study was to compare the safety and efficacy of aprepitant plus standard antiemetic therapy to placebo plus standard antiemetic therapy in patients receiving CYbased conditioning chemotherapy regimens prior to HSCT.
Patient population
Patients were included if they were 18 years of age or older, scheduled for an autologous or allogeneic bone marrow or peripheral blood stem cell transplant, had an Eastern Cooperative Oncology Group performance status ≤2, were able to swallow tablets and capsules, and received either myeloablative CY/total body irradiation (TBI) or targeted busulfan ( T Bu)/CY as their conditioning regimen. Patients were excluded if they had known sensitivity to aprepitant, ondansetron, or dexamethasone; received another investigational drug within the past 30 days; had emesis or required antiemetic agents in the 48 h prior to beginning conditioning therapy; had taken an NK 1 antagonist in the 14 days prior to enrollment; were pregnant, had positive serum hCG, or were lactating; had serum creatinine level ≥2 times the upper limit of normal; had severe hepatic insufficiency (Child-Pugh score >9); drank >5 alcoholic drinks/ day for the last year; or had concurrent illness requiring systemic corticosteroid use other than planned dexamethasone during conditioning therapy. Patients were randomized using permuted block randomization to receive either aprepitant or placebo in addition to our institution's standard antiemetic prophylaxis (ondansetron with dexamethasone). A randomization list was generated using a permuted block randomization with a random block size of either 2 or 4. The study statistician provided it to the investigational pharmacy dispensing the study medication. Patients randomized to placebo received an identical capsule containing cornstarch to patients randomized to aprepitant. The medications were administered on the same schedule to effectively blind the patients and healthcare staff.
Treatment description
Patients received aprepitant or placebo starting 1 h prior to the first chemotherapy or radiation dose of their conditioning regimen and continued aprepitant or placebo once daily until 4 days after the stem cell transplant procedure. All doses were encapsulated in identical capsules for aprepitant and dexamethasone. The dose of aprepitant was 125 mg by mouth for one dose on the first day of the conditioning regimen, followed by 80 mg by mouth once daily through day +4. The duration of aprepitant was extended to assess its impact on delayed nausea and vomiting and on its pharmacokinetics and drug interactions [9] . Ondansetron and dexamethasone were given per institutional guidelines on each day of chemotherapy or radiation as described in Appendix A. In the aprepitant arm, the dose of dexamethasone was reduced in a blinded fashion. Dexamethasone 12 mg by mouth for one dose was given on day 1, and 8 mg by mouth once daily was given on subsequent days. Rescue antiemetics were allowed per standard of care if patients experienced breakthrough nausea or vomiting. The choice, dose, route, and frequency of rescue medications were at the provider's discretion, but aprepitant was not used as a rescue agent. The medication name, dose, route, and number of doses of each agent were recorded in each subject's medication administration record.
Assessments
Patient signs and symptoms were assessed daily starting just prior to the first dose of chemotherapy through day +7 after stem cell infusion. Nausea and emesis were assessed during each nursing shift (twice daily) and documented in the patient electronic medical record per institutional standards. This documentation was verified using a quality of life (QOL)/nausea 100 mm visual analog scale (VAS) assessment form directly documented by the patient (Appendix B). Nurses recorded both retching and emesis as an emetic episode in the electronic medical record. Serum samples of substance P from nine patients in the placebo arm were assessed in a post hoc analysis.
Response definitions
Complete response (CR) was defined as the absence of emesis and the absence of mild to moderate nausea, as measured on the VAS assessment form (6-70 mm). Major response (MR) was defined as one to two episodes of emesis on a maximum of 1 day with any level of nausea or no emesis with severe nausea on a single day, as measured on the VAS assessment form (71-100 mm). Clinically beneficial response was defined as the addition of CR and MR. Minor response (mR) was defined as no more than one to two episodes of emesis on more than 1 day, but less than 3 days with any level of nausea. Finally, treatment failure (TF) was defined as greater than two episodes of emesis on any 1 day of the evaluation period or two emetic episodes on 3 or more days of the evaluation period. Of note, emesis occurring 2 h after infusion of dimethylsulfoxide-containing stem cells was not counted as an episode of emesis as described in the response definitions above.
Objectives
The primary objective of this study was to determine if there was a difference in the number of emesis-free days in patients who received aprepitant as compared to those who received placebo from the first day of conditioning to day +4. Secondary objectives were to assess the safety of aprepitant in the HSCT population, as well as to evaluate if there was a difference in the incidence of nausea, mucositis, appetite, and dysgeusia between the two study groups. Assessments were collected by patient report each day and scored by a pharmacist. Adverse event assessments were based on CTCAE and the worst score was documented.
Statistical methods
In a previously published study, an average of 4.6 emesis-free days during conditioning chemotherapy was observed (4.6 days in the standard therapy vs. 6.0 days in the aprepitant plus standard therapy) [10] . Using that data and assuming a standard deviation of 1.5, a sample size of 40 patients (20 in each group) would provide 80% power to detect a difference of 1.4 days. The sample size calculation was based on a twosample t-test with a 5% significance level.
The study was performed using an intention-to-treat analysis. A Wilcoxan rank sum test was used to compare the number of emesis-free and retch-free days between the aprepitant and placebo groups. Repeated measures analysis of variance was used to compare change in VAS and daily nutritional intake. Fisher's exact tests were used to evaluate the proportion of patients with treatment response and the frequency and severity of mucositis. 95% confidence intervals were calculated for treatment responses and the incidence of severe mucositis.
Safety
Toxicities and adverse events were graded according to National Cancer Institute Common Toxicity Criteria version 3.0. The exact 95% confidence interval of the toxicity rate was computed for each major toxicity category and for each group separately. The incidence of severe toxicity in each category was compared between the aprepitant and placebo groups using Fisher's exact test. The incidence of sinusoidal obstruction syndrome (SOS) was estimated for each group and compared using Fisher's exact test. If three cases of SOS in the aprepitant arm were observed at any time during the study period, the study would be closed immediately.
Results
Patient characteristics
A total of 40 patients were enrolled; 20 were randomized to the aprepitant group, and 20 were randomized to the placebo group. Seventeen patients received CY/TBI as their conditioning regimen, and 23 patients received T Bu/CY. Patient demographics are described in Table 1 . There were no significant differences between groups, and though patient indications for transplant varied between groups as noted in the table, the groups were too small to assess by disease state.
Efficacy
The average number of emesis-free days was 14.25 (standard deviation 1.48 days) in the aprepitant group compared to 12.45 days (standard deviation 2.16 days) for patients in the placebo group. Patient response rates for emesis and response rates by regimen are presented in Fig. 1 . Since the distribution of patients by preparative regimen was similar between aprepitant and placebo arms, as were the number of days for each preparative regimen, there was no weighting of emesis days between regimens for the primary outcome. Eight patients (40%) in the aprepitant group achieved CR as compared to four patients (20%) in the placebo group. MR was achieved in nine patients (45%) in the aprepitant group compared to five patients (25%) in the placebo group. There were two patients (10%) in each group who achieved mR. TF was observed in one patient (5%) in the aprepitant group as compared to nine patients (45%) in the placebo group. With regard to clinically beneficial responses, there was a significant difference in response rate that favored the aprepitant group (85% in the aprepitant group vs. 45% in the placebo group, P = 0.019). Eleven patients (55%) who received T Bu/Cy achieved a clinically beneficial response when they received aprepitant, compared with three patients (15%) in the placebo group. In patients who received CY/ TBI conditioning, 30% in both the aprepitant and placebo groups achieved a clinically beneficial response with no difference in benefit seen with the addition of aprepitant. Adherence to aprepitant, placebo, and other antiemetics was 100% as confirmed by recorded medication administration record times.
Cumulative incidence curves for the time to onset of first emesis episode and the time to first rescue antiemetic administration are shown in Figs. 2 and 3 , respectively. The aprepitant group experienced fewer emesis episodes overall: only one patient (5%) in the aprepitant group experienced emesis within the first 4 days of conditioning chemotherapy as compared to six patients (30%) in the placebo group. Approximately 100 h after conditioning chemotherapy began, recorded "first emesis episodes" increased in both groups. No patient had retching only. There was no difference between the two groups with regard to the time to first rescue antiemetic administered during the first 18 h after conditioning chemotherapy began. Between hours 20 and 100, there appeared to be a slight decrease in the time to the first rescue antiemetic being administered in patients treated in the aprepitant group.
Serum samples from nine patients in the placebo arm were assayed for substance P-levels as part of a post hoc analysis. The percent change of substance P-level between subsequent samples was calculated. Approximately 19 values per patient were analyzed. Substance P-levels increased with time in all patients from the start of the conditioning regimen with no discernable difference between conditioning regimens (data not shown).
QOL results
Patient-reported nausea symptoms are presented in Fig. 4 . In patients who experienced "no nausea", the QOL/nausea 100 mm VAS assessments were similar between the two groups on most days. However, more patients in the aprepitant group reported "no nausea" during the first 3 days of their conditioning regimen and on days 14 and 15 after conditioning began. Numerically, more patients in the placebo group experienced "mild nausea" compared to those in the aprepitant group throughout the study period. The number of patients who experienced "moderate nausea"
were similar between the two groups. Numerically, more patients in the aprepitant group experienced "severe nausea" as compared to those in the placebo group. Most patients who reported severe nausea symptoms did so on days 7 through 9.
Adverse events
The incidence of adverse events was similar in patients treated with aprepitant and placebo ( Table 2 ). Secondary outcomes of dysgeusia (5 vs. 0%), mucositis (75 vs. 90%), and anorexia (85 vs. 90%) were similar between those who received aprepitant and those who received placebo, respectively. Due to the effects of HSCT conditioning regimens, cytopenias were universal and were not reported. The most common nonhematologic adverse effects experienced were anorexia (87.5%) and diarrhea (85%). Vomiting, bloating, and elevated total bilirubin occurred more frequently in the placebo arm. Dyspepsia and flatulence occurred more frequently in the aprepitant arm. The mean time to neutrophil engraftment was 13.8 days and 14.95 days in the aprepitant and placebo group, respectively. Elevated total bilirubin occurred in three patients in the placebo group, but none met the criteria for SOS.
Discussion
This study evaluated the safety and efficacy of aprepitant when added to standard antiemetic prophylaxis in patients receiving highly emetogenic CY-containing conditioning regimens for autologous or allogeneic HSCT. The results of our study demonstrated a CR rate of 40% in patients in the aprepitant arm compared to 20% of patients in the placebo arm. This observation suggests that aprepitant confers additional benefit, although patients who received T Bu/Cy benefited more from aprepitant than those who received CY/TBI.
More patients in the aprepitant group reported "no nausea" during the first 3 days of their conditioning regimen, and numerically more patients in the placebo group reported "mild nausea" on days 2 through 15. However, QOL/nausea 100 mm VAS assessments were similar between the groups. More patients in the aprepitant group reported more "severe nausea" throughout the study period than those receiving placebo. This result suggests that aprepitant had a greater impact on decreasing the incidence of emesis than nausea.
Males tend to experience less nausea and emesis when treated with chemotherapy as compared to females [11] . Our study was not stratified by sex, so the impact that aprepitant may have on males and females may be variable.
Given the potential for drug interactions via CYP3A4 enzyme inhibition and the prolonged administration of aprepitant, safety was a key consideration in this study. Aprepitant was well tolerated by patients in this study. All side effects were manageable, and no cases of SOS were observed. The drug interaction between busulfan and aprepitant, however, cannot be ignored. In our study, only 12 patients received both aprepitant and busulfan. Pharmacokinetic analysis was performed on the first busulfan dose for all patients who received the chemotherapy agent, and if necessary, the busulfan dose was adjusted to achieve the target area under the curve. In those receiving concomitant busulfan and aprepitant, busulfan dose increases were required in three patients, dose decreases in six patients, and no dose change in three patients. In the nine patients receiving busulfan and placebo, busulfan dose increases were required in one patient, dose decreases in seven patients, and no dose change in one patient. Thus, though there were no discernable differences between groups, it is likely that therapeutic drug monitoring of busulfan may have increased the safety of using the two agents in combination. Previously published studies in HSCT populations found average CR rates of 45-67% on days 1 through 7 of conditioning when standard antiemetic regimens not containing aprepitant were used [3, 12, 13] . Recent studies have evaluated the use of aprepitant as part of an antiemetic regimen for highly emetogenic HSCT conditioning therapy. A prospective study by Paul and colleagues defined CR as "no emesis, none to mild nausea, and no breakthrough antiemetic use" [14] . The most common conditioning regimens used in this study were carmustine, etoposide, cytarabine, and melphalan (BEAM) or high-dose melphalan. The investigators found an average CR of 54% (range 42-73.8%) over days 1-7 following high-dose chemotherapy for HSCT when aprepitant was added to standard antiemetic therapy [14] . The majority of patients required breakthrough medications on day 7 of the study period (54.8%), though the exact number of medications administered was not reported [14] . A study by Pielichowski and colleagues evaluated response rates when aprepitant was given with a 5-HT3 receptor antagonist and dexamethasone in patients receiving BEAM conditioning chemotherapy. Antiemetic therapy was defined as "highly effective" when patients experienced either, (1) no emesis combined with none, mild, or moderate nausea (CR); or (2) one to two emetic episodes combined with none or mild nausea (MR) [15] . The authors reported a highly effective rate of 82% in the early and late phases of chemotherapy administration (days 0-5) when aprepitant was used [15] . Stiff and colleagues evaluated the addition of aprepitant to ondansetron and dexamethasone in patients who received conditioning regimens [16] . CR was defined as no emesis with no or mild nausea [16] . They reported an average CR rate of 81.9% on all study days in the aprepitant arm as compared to 65.8% in the placebo group (P < 0.001) [16] . Szer and colleagues reported preliminary results of a single-arm pilot study with aprepitant given through day 7 after HSCT or discharge. Of the 14 patients, 7 had total control of nausea and vomiting in the first week after HSCT, and 11 had total control in the second week after HSCT [17] . CR was not defined [17] . Bechtel and colleagues evaluated the efficacy of aprepitant as part of the antiemetic regimen for high-dose melphalan conditioning in multiple myeloma patients. CR was defined as no more than one emetic episode during the evaluation period (beginning 24 h after chemotherapy initiation and continuing until hour 120). Of the 26 patients who were enrolled, 25 (96%) achieved CR, and 24 (92%) had no documented emetic episodes [18] . Only 12% of patients required no breakthrough antiemetics [18] . In each of these studies, conditioning regimen heterogeneity and differing CR definitions limit the generalizability. The lower CR rate in our study compared to those described above could be attributed to the more strict definition of CR and the inclusion of CY-containing conditioning regimens.
Conclusion
In the setting of CY-containing myeloablative conditioning regimens prior to HSCT, aprepitant effectively decreased the incidence of emesis as compared to placebo when used in combination with ondansetron and dexamethasone in this study. Patients who received aprepitant before T Bu/Cy achieved a clinically beneficial response more frequently than those who received CY/TBI (55 vs. 30%, respectively). Aprepitant was well tolerated and safe when administered over a prolonged course.
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